ICON Public Limited Company

NasdaqGS ICLR

ICON Public Limited Company EBITDA Margin for the year ending December 31, 2023: 18.74%

ICON Public Limited Company EBITDA Margin is 18.74% for the year ending December 31, 2023, a 2.70% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • ICON Public Limited Company EBITDA Margin for the year ending December 31, 2022 was 18.24%, a 35.23% change year over year.
  • ICON Public Limited Company EBITDA Margin for the year ending December 31, 2021 was 13.49%, a -22.80% change year over year.
  • ICON Public Limited Company EBITDA Margin for the year ending December 31, 2020 was 17.48%, a -7.87% change year over year.
  • ICON Public Limited Company EBITDA Margin for the year ending December 31, 2019 was 18.97%, a 8.98% change year over year.
Key data
Date EBITDA Margin EBIT Margin Depreciation and Amortization EBIT
Market news
Loading...
SV Wall Street
NasdaqGS: ICLR

ICON Public Limited Company

CEO Dr. Steven A. Cutler MBA, Ph.D.
IPO Date May 15, 1998
Location Ireland
Headquarters South County Business Park
Employees 42,250
Sector Healthcare
Industries
Description

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Similar companies

QGEN

Qiagen N.V.

USD 44.64

0.29%

MEDP

Medpace Holdings, Inc.

USD 360.97

1.64%

NEOG

Neogen Corporation

USD 10.67

-0.93%

IQV

IQVIA Holdings Inc.

USD 209.96

2.20%

LH

Laboratory Corporation of America Holdings

USD 247.74

-0.90%

WAT

Waters Corporation

USD 410.95

-0.76%

CRL

Charles River Laboratories International, Inc.

USD 166.27

0.24%

TWST

Twist Bioscience Corporation

USD 53.70

0.07%

MTD

Mettler-Toledo International Inc.

USD 1.36 K

-0.46%

StockViz Staff

February 7, 2025

Any question? Send us an email